Tirzepatide has emerged as a groundbreaking medication for type 2 diabetes, offering promising outcomes. However, the expense of this innovative drug and its availability have become key topics for patients and healthcare practitioners. While tirzepatide has been cleared by regulatory agencies, its costly nature presents a significant obstacle to